Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $1.16 billion. The enterprise value is $1.40 billion.
| Market Cap | 1.16B |
| Enterprise Value | 1.40B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 84.09 million shares outstanding. The number of shares has increased by 5.97% in one year.
| Current Share Class | 68.31M |
| Shares Outstanding | 84.09M |
| Shares Change (YoY) | +5.97% |
| Shares Change (QoQ) | +1.19% |
| Owned by Insiders (%) | 2.64% |
| Owned by Institutions (%) | 42.36% |
| Float | 34.30M |
Valuation Ratios
The trailing PE ratio is 17.70 and the forward PE ratio is 17.35. Bioventus's PEG ratio is 1.58.
| PE Ratio | 17.70 |
| Forward PE | 17.35 |
| PS Ratio | 2.00 |
| Forward PS | 1.87 |
| PB Ratio | 4.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.34 |
| P/OCF Ratio | 12.01 |
| PEG Ratio | 1.58 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.43, with an EV/FCF ratio of 14.82.
| EV / Earnings | 25.65 |
| EV / Sales | 2.40 |
| EV / EBITDA | 17.43 |
| EV / EBIT | 23.05 |
| EV / FCF | 14.82 |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.95.
| Current Ratio | 1.69 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | 3.08 |
| Debt / FCF | 2.80 |
| Interest Coverage | 3.05 |
Financial Efficiency
Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 12.15%.
| Return on Equity (ROE) | 25.68% |
| Return on Assets (ROA) | 5.49% |
| Return on Invested Capital (ROIC) | 12.15% |
| Return on Capital Employed (ROCE) | 11.64% |
| Weighted Average Cost of Capital (WACC) | 7.49% |
| Revenue Per Employee | $612,472 |
| Profits Per Employee | $57,331 |
| Employee Count | 950 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 2.07 |
Taxes
| Income Tax | -22.84M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +84.78% in the last 52 weeks. The beta is 0.65, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +84.78% |
| 50-Day Moving Average | 12.40 |
| 200-Day Moving Average | 9.54 |
| Relative Strength Index (RSI) | 54.39 |
| Average Volume (20 Days) | 797,603 |
Short Selling Information
The latest short interest is 2.33 million, so 2.78% of the outstanding shares have been sold short.
| Short Interest | 2.33M |
| Short Previous Month | 2.54M |
| Short % of Shares Out | 2.78% |
| Short % of Float | 6.81% |
| Short Ratio (days to cover) | 2.94 |
Income Statement
In the last 12 months, Bioventus had revenue of $581.85 million and earned $54.46 million in profits. Earnings per share was $0.78.
| Revenue | 581.85M |
| Gross Profit | 399.45M |
| Operating Income | 60.61M |
| Pretax Income | 38.64M |
| Net Income | 54.46M |
| EBITDA | 80.15M |
| EBIT | 60.61M |
| Earnings Per Share (EPS) | $0.78 |
Balance Sheet
The company has $30.39 million in cash and $263.75 million in debt, with a net cash position of -$233.36 million or -$2.78 per share.
| Cash & Cash Equivalents | 30.39M |
| Total Debt | 263.75M |
| Net Cash | -233.36M |
| Net Cash Per Share | -$2.78 |
| Equity (Book Value) | 277.41M |
| Book Value Per Share | 3.35 |
| Working Capital | 105.08M |
Cash Flow
In the last 12 months, operating cash flow was $96.87 million and capital expenditures -$2.59 million, giving a free cash flow of $94.29 million.
| Operating Cash Flow | 96.87M |
| Capital Expenditures | -2.59M |
| Depreciation & Amortization | 19.54M |
| Net Borrowing | -27.90M |
| Free Cash Flow | 94.29M |
| FCF Per Share | $1.12 |
Margins
Gross margin is 68.65%, with operating and profit margins of 10.42% and 9.36%.
| Gross Margin | 68.65% |
| Operating Margin | 10.42% |
| Pretax Margin | 6.64% |
| Profit Margin | 9.36% |
| EBITDA Margin | 13.77% |
| EBIT Margin | 10.42% |
| FCF Margin | 16.20% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.97% |
| Shareholder Yield | -5.97% |
| Earnings Yield | 4.68% |
| FCF Yield | 8.10% |
Analyst Forecast
The average price target for Bioventus is $17.60, which is 27.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.60 |
| Price Target Difference | 27.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 6.56% |
| EPS Growth Forecast (3Y) | 15.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.54 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.54 |
| Piotroski F-Score | 8 |